Universidad de Buenos Aires, Hospital de Clínicas "José de San Martín", Departamento de Medicina, Buenos Aires, Argentina; Universidad de Buenos Aires, Facultad de Medicina, Buenos Aires, Argentina.
Universidad de Buenos Aires, Facultad de Medicina, Buenos Aires, Argentina.
Rev Argent Microbiol. 2023 Jul-Sep;55(3):246-250. doi: 10.1016/j.ram.2023.03.002. Epub 2023 Apr 26.
When a SARS-CoV-2 RT-qPCR test is performed, it may determine an indirect measure of viral load called cycle threshold (Ct). Respiratory samples with Ct <25.0 cycles are considered to contain a high viral load. We aimed to determine whether SARS-CoV-2 Ct at diagnosis could predict mortality in patients with hematologic malignancies (lymphomas, leukemias, multiple myeloma) who contracted COVID-19. We included 35 adults with COVID-19 confirmed by RT-qPCR performed at diagnosis. We evaluated mortality due to COVID-19 rather than mortality due to the hematologic neoplasm or all-cause mortality. Twenty-seven (27) patients survived and 8 died. The global mean Ct was 22.8 cycles with a median of 21.7. Among the survivors, the mean Ct was 24.2, and the median Ct value was 22.9 cycles. In the deceased patients, the mean Ct was 18.0 and the median Ct value was 17.0 cycles. Using the Wilcoxon Rank Sum test, we found a significant difference (p=0.035). SARS-CoV-2 Ct measured in nasal swabs obtained at diagnosis from patients with hematologic malignancies may be used to predict mortality.
当进行 SARS-CoV-2 RT-qPCR 检测时，它可能会确定一个称为循环阈值（Ct）的病毒载量的间接衡量标准。Ct 值<25.0 周期的呼吸道样本被认为含有高病毒载量。我们旨在确定在诊断时 SARS-CoV-2 的 Ct 是否可以预测患有血液恶性肿瘤（淋巴瘤、白血病、多发性骨髓瘤）并感染 COVID-19 的患者的死亡率。我们纳入了 35 名通过 RT-qPCR 确诊 COVID-19 的成年人。我们评估了因 COVID-19 导致的死亡率，而不是因血液恶性肿瘤或全因死亡率导致的死亡率。27 名（27 名）患者存活，8 名患者死亡。全球平均 Ct 值为 22.8 个周期，中位数为 21.7。在幸存者中，平均 Ct 值为 24.2，中位数 Ct 值为 22.9 个周期。在死亡患者中，平均 Ct 值为 18.0，中位数 Ct 值为 17.0 个周期。使用 Wilcoxon 秩和检验，我们发现存在显著差异（p=0.035）。从患有血液恶性肿瘤的患者中获得的鼻腔拭子中测量的 SARS-CoV-2 Ct 可能用于预测死亡率。
